Abstract
Given that mutant COL1A1 is known to cause Osteogenesis Imperfecta (OI), tools to modulate COL1A1 expression are likely to be of significant therapeutic value. In this context, we have evaluated RNA interference (RNAi) as a means to downregulate COL1A1 expression in Cos-7 cells and in human mesenchymal progenitor stem cells (MPCs), the latter cells giving rise to bone and therefore representing a target cell type for collagen-related disorders. In addition, allele-specificity, a key factor to the success of RNAi-based suppression, was explored with a view to developing a mutation-independent RNAi-based therapeutic for OI by targeting an intragenic SNP within transcripts derived from the COL1A1 gene. Preferential suppression of individual polymorphic alleles that differed by a single nucleotide was observed.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Millington-Ward S, O'Neill B, Tuohy G et al: Strategems in vitro for gene therapies directed to dominant mutations. Hum. Mol. Genet. 1997; 6: 1415–1426.
Millington-Ward S, O'Neill B, Kiang AS, Humphries P, Kenna PF, Farrar GJ : A mutation-independent therapeutic strategem for osteogenesis imperfecta. Antisense Nucleic Acid Drug Dev. 1999; 9: 537–542.
O'Neill B, Millington-Ward S, O'Reilly M et al: Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 2000; 41: 2863–2869.
Millington-Ward S, Allers C, Tuohy G et al: Validation in mesenchymal progenitor cells of a mutation-independent ex vivo approach to gene therapy for osteogenesis imperfecta. Hum. Mol. Genet. 2002; 11: 2201–2206.
Dykxhoorn DM, Novina CD, Sharp PA : Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. 2003; 4: 457–467.
Horwitz EM, Prockop DJ, Fitzpatrick LA et al: Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 1999; 5: 309–313.
Westerhausen AI, Constantinou CD, Prockop DJ : A sequence polymorphism in the 3′-nontranslated region of the pro alpha 1 chain of type I procollagen. Nucleic Acids Res. 1990; 18: 4968.
Altschul SF, Madden TL, Schaffer et al: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997; 25: 3389–3402.
Conget PA, Minguell JJ : Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J. Cell Physiol. 1999; 181: 67–73.
Ding H, Schwarz DS, Keene A et al: Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2003; 2: 209–217.
Miller VM, Xia H, Marrs GL et al: Allele-specific silencing of dominant disease genes. Proc. Natl. Acad. Sci. USA 2003; 100: 7195–7200.
Abdelgany A, Wood M, Beeson D : Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference. Hum. Mol. Genet. 2003; 12: 2637–2644.
Acknowledgements
We thank C Allers and P Conget for providing MPCs, and the CBBF, the Health Research Board Ireland and Enterprise Ireland for their support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Millington-Ward, S., McMahon, H., Allen, D. et al. RNAi of COL1A1 in mesenchymal progenitor cells. Eur J Hum Genet 12, 864–866 (2004). https://doi.org/10.1038/sj.ejhg.5201230
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.ejhg.5201230
Keywords
This article is cited by
-
Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta
European Journal of Human Genetics (2014)
-
Therapeutic application of mesenchymal stem cells in bone and joint diseases
Clinical and Experimental Medicine (2014)
-
Orthopedic Gene Therapy in 2008
Molecular Therapy (2009)
-
Small interfering RNA of alkaline phosphatase inhibits matrix mineralization
Cell and Tissue Research (2008)
-
Treatment of children with osteogenesis imperfecta
Current Osteoporosis Reports (2006)
